Simplex Trading
BCRX icon

Simplex Trading’s BioCryst Pharmaceuticals BCRX Stock Holding History

Simplex Trading’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$330K Buy
+34,700
New +$269K ﹤0.01% 3719
2025
Q4 		– Sell
-84,200
Closed -$639K – 8556
2025
Q3 		$639K Sell
84,200
-22,600
-21% -$188K ﹤0.01% 3530
2025
Q2 		$956K Buy
106,800
+23,800
+29% +$222K ﹤0.01% 2827
2025
Q1 		$622K Sell
83,000
-3,800
-4% -$30.7K ﹤0.01% 3155
2024
Q4 		$652K Buy
86,800
+23,100
+36% +$175K ﹤0.01% 3270
2024
Q3 		$484K Buy
63,700
+15,600
+32% +$119K ﹤0.01% 3622
2024
Q2 		$297K Sell
48,100
-5,600
-10% -$30.9K ﹤0.01% 4236
2024
Q1 		$272K Buy
53,700
+42,900
+397% +$241K ﹤0.01% 4510
2023
Q4 		$64K Sell
10,800
-32,000
-75% -$185K ﹤0.01% 5842
2023
Q3 		$303K Buy
42,800
+9,500
+29% +$68.3K ﹤0.01% 3929
2023
Q2 		$234K Sell
33,300
-78,300
-70% -$628K ﹤0.01% 4116
2023
Q1 		$930K Buy
111,600
+23,900
+27% +$230K ﹤0.01% 2661
2022
Q4 		$1.01M Buy
87,700
+32,100
+58% +$400K ﹤0.01% 2454
2022
Q3 		$700K Sell
55,600
-180,600
-76% -$2.32M ﹤0.01% 3077
2022
Q2 		$2.5M Buy
236,200
+177,900
+305% +$1.84M ﹤0.01% 1661
2022
Q1 		$947K Sell
58,300
-45,900
-44% -$736K ﹤0.01% 2992
2021
Q4 		$1.44M Sell
104,200
-54,900
-35% -$727K ﹤0.01% 2402
2021
Q3 		$2.59M Buy
159,100
+13,700
+9% +$216K ﹤0.01% 1836
2021
Q2 		$2.3M Buy
+145,400
New +$1.98M ﹤0.01% 1990
2021
Q1 		– Sell
-2,011
Closed -$1.5M – 8805
2020
Q4 		$1.5M Buy
2,011
+1,482
+280% +$7.64K ﹤0.01% 2070
2020
Q3 		$181K Buy
529
+508
+2,419% +$2.18K ﹤0.01% 4237
2020
Q2 		$10K Buy
21
+6
+40% +$24 ﹤0.01% 6639
2020
Q1 		$3K Sell
15
-27
-64% -$74 ﹤0.01% 7033
2019
Q4 		$14K Buy
42
+28
+200% +$70 ﹤0.01% 6177
2019
Q3 		$4K Sell
14
-232
-94% -$722 ﹤0.01% 6671
2019
Q2 		$93K Buy
246
+220
+846% +$1.32K ﹤0.01% 4260
2019
Q1 		$21K Buy
26
+8
+44% +$68 ﹤0.01% 5675
2018
Q4 		$14K Buy
+18
New +$140 ﹤0.01% 5603
2018
Q2 		– Sell
-53
Closed -$6K – 7353
2018
Q1 		$6K Buy
+53
New +$272 ﹤0.01% 4438
2017
Q4 		– Sell
-371
Closed -$11K – 5976
2017
Q3 		$11K Sell
371
-277
-43% -$1.42K ﹤0.01% 3667
2017
Q2 		$88K Buy
648
+572
+753% +$3.48K ﹤0.01% 1863
2017
Q1 		$3K Sell
76
-55
-42% -$383 ﹤0.01% 4932
2016
Q4 		$30K Buy
131
+78
+147% +$406 ﹤0.01% 2646
2016
Q3 		$2K Buy
53
+51
+2,550% +$204 ﹤0.01% 4888
2016
Q2 		$1K Sell
2
-4
-67% -$12 ﹤0.01% 5210
2016
Q1 		$3K Sell
6
-16
-73% -$71 ﹤0.01% 4414
2015
Q4 		$1K Sell
22
-24
-52% -$239 ﹤0.01% 4780
2015
Q3 		$5K Buy
+46
New +$614 ﹤0.01% 3955
2015
Q2 		– Sell
-9
Closed -$1K – 5171
2015
Q1 		$1K Sell
9
-240
-96% -$2.48K ﹤0.01% 4397
2014
Q4 		$15K Buy
+249
New +$2.75K ﹤0.01% 2264

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Simplex Trading's BCRX Position: Q1 2026 in Review

Simplex Trading opened a new position in BioCryst Pharmaceuticals (BCRX) in Q1 2026: 53,965 shares worth $514K. The stake represents ﹤0.01% of the portfolio and ranks #3224 among its holdings. This is a return to the name: Simplex Trading previously reported a position in BCRX as recently as Q3 2025.

Simplex Trading first reported a position in BCRX in Q4 2014 and has held it in 27 quarters since. The position peaked at $1.87M in Q4 2020. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Simplex Trading held 53,965 shares of BioCryst Pharmaceuticals worth $514K as of Q1 2026.
  • BioCryst Pharmaceuticals was a new Simplex Trading position in Q1 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #3224 holding.
  • Simplex Trading first reported a position in BioCryst Pharmaceuticals in Q4 2014 and has held it in 27 quarters since.
  • Simplex Trading's BioCryst Pharmaceuticals position peaked at $1.87M in Q4 2020.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.